VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 25th …
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three …
Net Assets Increases to $30.4 Million From $29.0 Million Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule …
ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature-controlled logistics real estate, and value-added services focused on the ownership, operation, acquisition, and …
EXPLORER-CN研究数据在欧洲心脏病学会年会（ESC）Late-Breaking专场上以口头报告方式公布 试验数据同步发表于《JAMA Cardiology》 Mavacamten（玛伐凯泰）在中国梗阻性肥厚型心肌病（oHCM）患者的Valsalva 左心室流出道峰值压差、左心室流出道梗阻、临床症状、健康状况、心脏生物标志物和心脏结构等方面均显示出改善 研究证实，先前确定的 mavacamten（玛伐凯泰）的有效性同样适用于中国患者 上海和新泽西州普林斯顿, Aug. 29, 2023 (GLOBE …
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak gradient, LVOT obstruction, clinical symptoms, health …
SALT LAKE CITY, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announced that the Company’s Board of Directors has declared a …
- Q2 Revenue up 9% Sequentially and YoY to $24.4 Million - - Q2 Cash from Operations of $4.8 Million; 7th Consecutive Quarter of Positive Cash Flow - TAMPA, Fla., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) (“Cansortium” …
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported …
WASHINGTON -- As the Biden-Harris Administration continues response and recovery actions in Hawaii, the federal government is also closely monitoring Tropical Storm Idalia and encouraging residents in the storm’s path to get prepared today. President …
Madison, Miss. – FEMA is asking homeowners and renters in Jackson and Jasper counties who applied for disaster assistance to answer their phones -- even if the call is from an unknown number. FEMA knows that many people do not answer calls from unknown …
PHILADELPHIA - Federal Emergency Management Agency (FEMA) Senior Officials, Victoria Salinas and Janice Barlow, toured DC Water’s Blue Plains Advanced Wastewater Treatment Plant to celebrate Disaster Resilience Month this August. The tour highlighted the …
Today, Homeland Security Secretary Alejandro N. Mayorkas, FEMA Administrator Deanne Criswell, and Senior Advisor to the President and White House Infrastructure Coordinator Mitch Landrieu announced project selections for nearly $3 billion in climate …
The U.S. Army Corps of Engineers (USACE) reached a milestone this week as Typhoon Mawar debris clean-up from residential rights of way (ROWs), has been finished three villages (Humatak, Malesso, Piti.) The debris mission continues in 12 villages with the …
With debris clean-up teams on the ground, The U.S. Army Corps of Engineers (USACE) debris mission continues with three new villages (Chalan Pago, Mangilao, and Yona) beginning debris clean-up this week. Residents are encouraged to complete their debris …
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for dermatomyositis Mechelen, …
GLPG3667 is een nieuwe, orale, reversibele en selectieve tyrosinekinase 2 (TYK2)-remmer in onderzoek GLPG3667 is momenteel in ontwikkeling voor de behandeling van ontstekings- en auto-immuunziekten en bevindt zich in fase 2 voor dermatomyositis Mechelen, …
The summer is hot but here is a breeze of security news to cool you down. We have been busy during the summer months, and here are the news: INNSBRUCK, TIROL, AUSTRIA, August 28, 2023 /EINPresswire.com/ -- The summer is hot but here is a breeze of …
THORNTON, Colo., Aug. 28, 2023 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United …
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that members of its management team will participate in the following investor …
